Publicaciones científicas sobre los diagnósticos no invasivos de BioPredictive

Estudios revisados por pares que validan los diagnósticos por análisis de sangre de BioPredictive para enfermedades hepáticas — desde cohortes de desarrollo pioneras hasta metaanálisis a largo plazo.

205/435 Coincidencias para
“liver injury”

“liver injury” Borrar todo
  1. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Coinc. 100

    …better biomarkers of drug-induced-liver-injury (DILI). ### Aims We aimed to…

    ActiTest FibroTest Other

  2. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.

    Mahamid M et al. · Clin Pharmacol · 2011 Coinc. 100

    …Other possible etiologies for liver injury were excluded. Discontinuation of anakinra led…

    FibroTest Other

  3. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Coinc. 100

    ActiTest AshTest FibroTest NashTest +6

  4. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Coinc. 100

    liver injury. ### Conclusion A number of non-invasive markers of liver damage…

    NashTest SteatoTest Metabolic

  5. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Coinc. 100

    …transferrin (CDT%), is confounded by liver disease severity. The aim was to…

    FibroTest SteatoTest Alcohol

  6. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.

    Ratziu V et al. · Aliment Pharmacol Ther · 2007 Coinc. 99

    …It is impossible to perform liver biopsy in such a large number…

    FibroTest NashTest SteatoTest Metabolic

  7. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Coinc. 99

    ### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…

    FibroTest NashTest SteatoTest Metabolic

  8. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis

    Poynard T et al. · PLoS One · 2012 Coinc. 99

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    ActiTest FibroTest NashTest SteatoTest +1

  9. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Coinc. 99

    …Progressive liver injury is a concern in HIV-infected children exposed to…

    FibroTest HIV

  10. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Coinc. 98

    …severity of nocturnal hypoxia and liver injury was established only in morbid…

    FibroTest NashTest SteatoTest Metabolic

  11. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.

    Berends MA et al. · Liver Int · 2007 Coinc. 98

    …To monitor this serial liver biopsies were performed. The Fibroscan and the…

    FibroTest Other

  12. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.

    Knop V et al. · Nutrition · 2019 Coinc. 98

    …risk for intestinal failure-associated liver disease (IFALD). The aim of the…

    FibroTest SteatoTest Other

  13. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Coinc. 98

    ActiTest AshTest FibroTest NashTest +7

  14. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Key publication

    Poynard T et al. · Clin Chem · 2004 Coinc. 97

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury

    ActiTest FibroTest HCV

  15. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.

    Dominguez S et al. · J Antimicrob Chemother · 2010 Coinc. 97

    …infected patients with liver disease documented by liver biopsy, matched with HIV…

    FibroTest HCV HIV

  16. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Coinc. 97

    …Steatosis was demonstrated in all 5 patients who received liver biopsies during…

    FibroTest Other

  17. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

    Poynard T et al. · Comp Hepatol · 2004 Coinc. 97

    …alternative to liver biopsy for the assessment of liver injury in patients…

    ActiTest FibroTest HCV

  18. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Coinc. 96

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  19. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Coinc. 96

    FibroTest Alcohol

  20. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Coinc. 96

    ActiTest FibroTest Alcohol HBV +3

  21. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Coinc. 96

    Liver biopsy, owing to its limitations and risks, is an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  22. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Coinc. 95

    …of non-invasive biomarkers in liver fibrosis. A scoring system has been…

    ActiTest FibroTest SteatoTest Alcohol +5

  23. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Coinc. 95

    ### Background Liver biopsy is considered the gold standard for assessing histologic lesions…

    NashTest Metabolic

  24. Non-invasive markers for hepatic fibrosis. Review

    Baranova A et al. · BMC Gastroenterol · 2011 Coinc. 95

    …The rate of adoption of non-invasive diagnostic tests for liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  25. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Coinc. 95

    …Non-invasive diagnostics of liver injury may be useful in screening to…

    ActiTest FibroTest SteatoTest Metabolic

  26. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Key publication

    Halfon P et al. · Am J Gastroenterol · 2006 Coinc. 94

    …a non-invasive alternative to liver biopsy in patients with chronic hepatitis…

    ActiTest FibroTest HCV

  27. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2013 Coinc. 94

    FibroTest Metabolic

  28. [The prediction and validation of liver fibrosis by a noninvasive model and validation in patients with chronic hepatitis B].

    Liu WP et al. · Zhonghua Nei Ke Za Zhi · 2008 Coinc. 94

    ### Objective To develop a simple model for the noninvasive diagnosis of liver

    FibroTest HBV

  29. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Coinc. 94

    …As for the prediction of liver injury, the concordance between fasting and…

    ActiTest FibroTest Alcohol HBV +3

  30. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. Review

    Lombardi R et al. · World J Gastroenterol · 2015 Coinc. 93

    …of alcohol-related liver injury is histology, liver biopsy is not reasonable…

    FibroTest Alcohol

  31. Glycogenic hepatopathy. Review

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Coinc. 93

    …GH may be diagnosed also after elevated liver enzymes in routine blood…

    FibroTest Metabolic

  32. FibroMAX: towards a new universal biomarker of liver disease? Review

    Morra R et al. · Expert Rev Mol Diagn · 2007 Coinc. 93

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  33. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Coinc. 93

    …Among the 2,169 patients who underwent liver biopsy, bridging fibrosis (F2…

    FibroTest HCV

  34. Biomarkers of liver fibrosis. Review

    Poynard T et al. · Adv Clin Chem · 2008 Coinc. 92

    Liver biopsy, due to its limitations and risks, is an imperfect gold…

    ActiTest FibroTest SteatoTest Alcohol +5

  35. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Coinc. 92

    ### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…

    FibroTest HCV

  36. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Coinc. 92

    FibroTest Metabolic

  37. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Key publication

    Hermeziu B et al. · Gastroenterol Clin Biol · 2010 Coinc. 92

    …as a noninvasive alternative to liver biopsy (LB), but there are few…

    ActiTest FibroTest HCV

  38. Liver biopsy: the best standard...when everything else fails.

    Poynard T et al. · J Hepatol · 2009 Coinc. 91

    FibroTest Alcohol HBV HCV +1

  39. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Coinc. 91

    …vs placebo was assessed on liver injury according to baseline stage and…

    ActiTest FibroTest HBV

  40. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Meta Analysis

    Poynard T et al. · Antivir Ther · 2010 Coinc. 91

    ### Background Liver biopsy and virological end points are standard references for assessing…

    ActiTest FibroTest HBV HCV +1

  41. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013 Coinc. 91

    …Four cases of primary liver cancer occurred in SVR [4.6% (0…

    FibroTest HCV

  42. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Coinc. 90

    …Fatty liver was diagnosed with abdominal ultrasound and liver steatosis was quantified…

    FibroTest SteatoTest Metabolic

  43. HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.

    Costa JM et al. · Clin Res Hepatol Gastroenterol · 2011 Coinc. 90

    ### Background And Aim Three gene polymorphisms, interferon-lambda-3 (IL28B), inosinetriphosphatase (ITPA…

    ActiTest FibroTest HCV-GenoFibroTest SteatoTest +1

  44. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Coinc. 90

    …followed for a risk of liver fibrosis risk in the USA (212…

    FibroTest Other

  45. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012 Coinc. 90

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight…

    Metabolic

  46. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Coinc. 90

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  47. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference. Key publication

    Peta V et al. · World J Hepatol · 2025 Coinc. 89

    ActiTest FibroTest Autoimmune hepatitis

  48. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Key publication

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Coinc. 89

    …Ten year survival (95% CI) without liver-related death in patients with…

    FibroTest Alcohol HBV HCV +1

  49. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Coinc. 89

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    FibroTest Metabolic

  50. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Key publication

    Thiele M et al. · Gastroenterology · 2018 Coinc. 89

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  51. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Coinc. 88

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  52. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Coinc. 88

    …major determinant of progression of liver injury. This study evaluated FibroMax™ for…

    HCV

  53. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Coinc. 88

    …antifibrotic properties and may reduce liver injury in NASH. To date, no…

    FibroTest Metabolic

  54. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Coinc. 88

    …The best marker of liver fibrosis in alcoholic patients seems to be…

    FibroTest Alcohol

  55. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Meta Analysis

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Coinc. 87

    ### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…

    ActiTest HCV

  56. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Coinc. 87

    liver function tests will miss most patients with significant liver injury. New…

    FibroTest Other

  57. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Coinc. 87

    …SVR benefits are well-recognized with reductions in rates of liver complications…

    FibroTest HCV

  58. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Coinc. 87

    …of liver disease severity. ### Objective To compare the awareness of liver disease…

    ActiTest FibroTest Alcohol HBV +3

  59. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.

    Friedrich-Rust M et al. · J Thorac Cardiovasc Surg · 2008 Coinc. 86

    …Transient elastography has been evaluated for noninvasive staging of liver fibrosis in…

    ActiTest FibroTest Other

  60. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Coinc. 86

    ### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver

    FibroTest SteatoTest Metabolic

  61. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Coinc. 86

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  62. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Coinc. 86

    ### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  63. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review

    Ahmad W et al. · Virol J · 2011 Coinc. 85

    …Although, liver biopsy is still considered as gold standard to identify liver

    FibroTest HCV

  64. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication

    Poynard T et al. · Diagnostics (Basel) · 2025 Coinc. 85

    …2-diabetes (T2D), obesity, and liver fibrosis (resmetirom) announce the widespread use…

    FibroTest-T2D Metabolic

  65. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Coinc. 85

    liver pathologies, and provide accurate staging of the degree of liver injury

    FibroTest Alcohol

  66. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.

    Morra R et al. · Aliment Pharmacol Ther · 2007 Coinc. 85

    ### Background FibroTest has been validated for the diagnosis of liver fibrosis in…

    FibroTest Alcohol HBV HCV +1

  67. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Coinc. 84

    …CHB and its consequences on liver injury compared with CHC and NAFLD…

    FibroTest SteatoTest HBV HCV +1

  68. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Coinc. 84

    ### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…

    FibroTest HCV

  69. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.

    Carlson JJ et al. · J Gastroenterol Hepatol · 2009 Coinc. 84

    …In comparison with liver biopsy alone, there was a cost savings of…

    FibroTest

  70. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Coinc. 84

    …in the prediction of primary liver cancer in patients without cirrhosis. ### Aim…

    LCR1 LCR2 Alcohol HBV +4

  71. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

    Poynard T et al. · Aliment Pharmacol Ther · 2007 Coinc. 83

    …the entire liver and one taking into account the prevalence of each…

    FibroTest HCV

  72. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Coinc. 83

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  73. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Coinc. 83

    …primary liver cancer, variceal bleeding, or decompensation (ascites, encephalopathy, or jaundice). ### Methods…

    FibroTest HCV

  74. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.

    Montaudié H et al. · J Eur Acad Dermatol Venereol · 2011 Coinc. 83

    …ideal method for monitoring the liver toxicity of MTX in the management…

    FibroTest Other

  75. Noninvasive assessment of portal hypertension in patients with cirrhosis. Review

    Thabut D et al. · Hepatology · 2011 Coinc. 82

    Severe portal hypertension is responsible for complications and death. Although measurement of…

    FibroTest Alcohol HBV HCV +3

  76. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.

    Poynard T et al. · Am J Gastroenterol · 2005 Coinc. 82

    …AT), are an alternative to liver biopsy in patients with chronic hepatitis…

    ActiTest FibroTest HBV

  77. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

    Grigorescu M et al. · J Gastrointestin Liver Dis · 2007 Coinc. 82

    …in order to avoid the liver biopsy currently used for selection of…

    FibroTest HCV

  78. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Coinc. 82

    Liver disease in UCDs may be associated with hepatic inflammation, hepatic fibrosis…

    ActiTest FibroTest Other

  79. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Coinc. 81

    FibroTest Metabolic

  80. FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.

    Munteanu M et al. · Liver Int · 2014 Coinc. 81

    FibroTest HBV

  81. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Coinc. 81

    ActiTest FibroTest HCV

  82. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Coinc. 81

    …The optimal cut-off values of liver stiffness (LS) for predicting METAVIR…

    FibroTest Alcohol

  83. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Coinc. 80

    ### Aim The objective of this study was to evaluate liver fibrosis using…

    FibroTest Metabolic

  84. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Coinc. 80

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  85. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Coinc. 80

    …For the prediction of survival without liver-related death, the areas under…

    FibroTest Alcohol HBV HCV +3

  86. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Coinc. 80

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  87. Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

    Fontanges T et al. · Gastroenterol Clin Biol · 2008 Coinc. 80

    …practice and in comparison with liver biopsy the limitations of two blood…

    ActiTest FibroTest HCV

  88. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Coinc. 79

    FibroTest SteatoTest Metabolic

  89. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Coinc. 79

    …evaluated for the assessment of liver fibrosis predominantly in patients with viral…

    FibroTest SteatoTest Other

  90. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication

    Poynard T et al. · Clin Chem · 2007 Coinc. 79

    ### Background The area under the ROC curve (AUC) is widely used as…

    FibroTest HCV

  91. Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?

    Ofei SY et al. · Int J Cardiol · 2015 Coinc. 79

    FibroTest Other

  92. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Coinc. 78

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  93. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Coinc. 78

    ### Background Biopsy is the usual gold standard for liver steatosis assessment. The…

    SteatoTest Alcohol HBV HCV +1

  94. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Review

    Parikh P et al. · Ann Transl Med · 2017 Coinc. 78

    Chronic hepatitis B virus (HBV) infection is a major cause of liver

    FibroTest HBV

  95. Non-invasive diagnosis of hepatitis B virus-related cirrhosis. Review

    Lee S et al. · World J Gastroenterol · 2014 Coinc. 78

    Liver biopsy is the reference standard for assessment of liver fibrosis. However…

    FibroTest HBV

  96. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Coinc. 77

    ### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…

    FibroTest HCV HIV

  97. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Coinc. 77

    …The main endpoint was the absence of liver-related complications, transplantation or…

    ActiTest FibroTest HCV

  98. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.

    Chládek J et al. · J Eur Acad Dermatol Venereol · 2013 Coinc. 77

    …However, its use is hampered by the risk of liver fibrosis. ### Aim…

    FibroTest Other

  99. Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.

    Munteanu M et al. · Am J Gastroenterol · 2014 Coinc. 77

    FibroTest HBV

  100. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Coinc. 76

    …these findings in women and in people with other chronic liver diseases.

    FibroTest HCV

  101. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2012 Coinc. 76

    ### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…

    Elasto-FibroTest FibroTest HCV

  102. Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.

    Brühl J et al. · Eur J Gastroenterol Hepatol · 2011 Coinc. 76

    …Results of noninvasive liver fibrosis markers were as follows: fibrotest,-1.65…

    FibroTest Other

  103. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Coinc. 76

    …FibroSure; LabCorp, Burlington, USA) and liver stiffness measurement (LSM) by Fibroscan (Echosens…

    FibroTest HBV

  104. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.

    Stibbe KJ et al. · Scand J Gastroenterol · 2011 Coinc. 75

    ### Objective Chronic viral hepatitis B and C cause liver fibrosis, leading to…

    FibroTest HBV HCV

  105. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review

    Festi D et al. · Aliment Pharmacol Ther · 2013 Coinc. 75

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  106. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection

    · 2015 Coinc. 75

    …to assess the stage of liver disease and eligibility for treatment; prioritize…

    FibroTest HBV

  107. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Coinc. 75

    ### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…

    FibroTest Other

  108. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Coinc. 74

    ### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…

    FibroTest Alcohol HBV HCV +1

  109. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Coinc. 74

    The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea…

    FibroTest NashTest SteatoTest Metabolic

  110. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Coinc. 74

    …and TE were predictive of liver complications (n=37; AUROC=0.83…

    ActiTest FibroTest HBV

  111. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Coinc. 74

    …patients with chronic liver disease or normal liver tissue that surrounded tumors…

    FibroTest Alcohol HBV HCV +3

  112. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. Key publication

    Peta V et al. · Clin Res Hepatol Gastroenterol · 2020 Coinc. 73

    …gamma-carboxy prothrombin (DCP) and Liver-Cancer-Risk-test (LCR1-test). ### Methods…

    ActiTest FibroTest Alcohol HBV +2

  113. The non-invasive assessment of hepatic fibrosis. Review

    Gheorghe G et al. · J Formos Med Assoc · 2021 Coinc. 73

    Liver fibrosis, as the last stage of numerous chronic liver diseases, is…

    ActiTest FibroTest Alcohol HBV +2

  114. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Coinc. 73

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  115. [The diagnostic value of non-invasive biochemical biomarkers in alcohol abuse].

    Supronowicz Ł et al. · Pol Merkur Lekarski · 2013 Coinc. 73

    ### Unlabelled The diagnosis of alcoholic liver disease, steatosis, fibrosis and alcoholic steatohepatitis…

    AshTest FibroTest SteatoTest Alcohol

  116. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

    Poynard T et al. · Hepatology · 2003 Coinc. 72

    …Three hundred fifty-two patients who had had 2 interpretable liver biopsies…

    ActiTest FibroTest HCV

  117. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Coinc. 72

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  118. Meta-analyses of FibroTest diagnostic value in chronic liver disease. Key publication Meta Analysis

    Poynard T et al. · BMC Gastroenterol · 2007 Coinc. 72

    ### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…

    FibroTest Alcohol HBV HCV +1

  119. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.

    Poynard T et al. · J Hepatol · 2011 Coinc. 72

    ### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…

    FibroTest HCV

  120. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Review

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Coinc. 71

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  121. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Coinc. 71

    …the final result of injury to the liver. Accurate assessment of the…

    FibroTest SteatoTest HBV HCV +1

  122. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Coinc. 71

    …for the diagnostic of metabolic liver disease in patients with type-2…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  123. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication

    Deckmyn O et al. · Biomedicines · 2022 Coinc. 71

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  124. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Coinc. 70

    ### Introduction Identifying liver fibrosis is important to evaluate the severity of liver

    FibroTest

  125. American Association for the Study of the Liver

    Coinc. 70

    FibroTest HCV

  126. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.

    Haseltine EL et al. · J Viral Hepat · 2015 Coinc. 70

    Patients infected with hepatitis C virus (HCV) have differing levels of liver

    FibroTest HCV

  127. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Coinc. 70

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  128. The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.

    Sökücü S et al. · Scand J Infect Dis · 2010 Coinc. 70

    …decreases the need for a liver biopsy. Twenty-five children with naïve…

    ActiTest FibroTest HBV

  129. A simple biological index for detection of alcoholic liver disease in drinkers.

    Poynard T et al. · Gastroenterology · 1991 Coinc. 69

    To make liver biopsy unnecessary in certain cases, PGA (P, prothrombin time…

    Alcohol

  130. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Coinc. 69

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver

    FibroTest HCV

  131. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Coinc. 69

    ActiTest FibroTest HCV

  132. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Coinc. 69

    …Given that early identification of non-alcoholic fatty liver disease (NAFLD) is…

    NashTest SteatoTest Metabolic

  133. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Coinc. 68

    The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…

    ActiTest FibroTest NashTest SteatoTest +1

  134. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Coinc. 68

    Liver biopsy, because of its limitations and risks, might be considered an…

    ActiTest FibroTest HCV

  135. Hepatitis B: are non-invasive markers of liver fibrosis reliable? Review

    Castera L · Liver Int · 2014 Coinc. 68

    …However, as none are liver specific their results can be influenced by…

    FibroTest HBV HCV

  136. Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.

    Yakoob R et al. · Ann Gastroenterol · 2015 Coinc. 68

    …hepatitis C (CHC) patients with liver biopsy (LB). ### Methods In 107 patients…

    ActiTest FibroTest HCV

  137. Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores.

    Férard G et al. · Clin Chem Lab Med · 2006 Coinc. 67

    liver fibrosis or necro-inflammatory lesions as an alternative to liver biopsy…

    ActiTest FibroTest HBV HCV

  138. Effective use of FibroTest to generate decision trees in hepatitis C.

    Lau-Corona D et al. · World J Gastroenterol · 2009 Coinc. 67

    …chronic hepatitis C without a liver biopsy. The FibroTest attributes of age…

    FibroTest HCV

  139. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Coinc. 67

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  140. Liver fibrosis markers in alcoholic liver disease. Review

    Chrostek L et al. · World J Gastroenterol · 2014 Coinc. 67

    Alcohol is one of the main factors of liver damage. The evaluation…

    FibroTest Alcohol

  141. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Coinc. 66

    Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…

    FibroTest HCV

  142. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Coinc. 66

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  143. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Coinc. 66

    Fontan-associated liver disease (FALD) is a serious complication related to the…

    FibroTest Other

  144. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.

    Canbakan M et al. · Nephron Clin Pract · 2011 Coinc. 66

    ### Background Liver biopsy is an imperfect gold standard for assessing the disease…

    FibroTest HCV

  145. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Coinc. 65

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver

    FibroTest Other

  146. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.

    Wu FM et al. · J Heart Lung Transplant · 2017 Coinc. 65

    …Further studies are needed to guide strategies for surveillance of liver disease…

    FibroTest Other

  147. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Coinc. 65

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  148. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Coinc. 65

    …The use of FT may decrease the need for liver biopsy examination.

    FibroTest Alcohol

  149. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

    Friedrich-Rust M et al. · BMC Gastroenterol · 2010 Coinc. 64

    …The Enhanced Liver Fibrosis (ELF) test consists of an algorithm of three…

    FibroTest HBV HCV Other

  150. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.

    Dai CY et al. · J Hepatol · 2010 Coinc. 64

    ### Background & Aims Hepatitis C virus (HCV) infection has been shown to be…

    FibroTest HBV HCV

  151. Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics.

    Schleiger A et al. · Pediatr Cardiol · 2020 Coinc. 64

    …Severe liver cirrhosis was detectable in 20 patients (17.1%). Median liver

    FibroTest Other

  152. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Coinc. 64

    …42.6 +/- 11.3) with CHB undergoing diagnostic liver biopsy were included…

    FibroTest HBV

  153. Altered serum N-glycomics in chronic hepatitis B patients.

    Gui HL et al. · Liver Int · 2010 Coinc. 63

    …markers for the diagnosis of liver fibrosis in patients with chronic hepatitis…

    FibroTest HBV

  154. Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.

    Bosselut N et al. · Clin Chim Acta · 2013 Coinc. 63

    ### Background Noninvasive methods for liver fibrosis evaluation in chronic liver diseases have…

    FibroTest HCV

  155. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

    Calin R et al. · J Clin Virol · 2013 Coinc. 63

    …The dynamic of liver disease in co-infected patients is important to…

    FibroTest HBV HIV

  156. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003 Coinc. 63

    ### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…

    ActiTest FibroTest HBV

  157. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Coinc. 62

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  158. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Coinc. 62

    Liver-related and non-liver-related outcomes were documented. Overall 213 episodes…

    FibroTest HCV HIV

  159. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.

    Corradi F et al. · Dig Liver Dis · 2009 Coinc. 62

    ### Background Progression of recurrent hepatitis C is accelerated in liver transplant recipients…

    FibroTest HCV

  160. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.

    d'Arondel C et al. · J Viral Hepat · 2006 Coinc. 62

    In therapy with standard interferon and ribavirin, five independent risk factors (RF…

    ActiTest FibroTest HCV

  161. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Coinc. 61

    …confirmed by Fibromax testing (or liver biopsy/Fibroscan). Efficacy was assessed by…

    FibroTest HCV

  162. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Coinc. 61

    ### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…

    FibroTest Alcohol

  163. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Coinc. 61

    …We reviewed the landmark studies in metabolic liver disease, sources of the…

    ActiTest FibroTest NashTest NashTest-2 +3

  164. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Coinc. 61

    …Histologic staging of liver fibrosis served as the reference standard. ### Results Liver

    FibroTest Alcohol HBV HCV +2

  165. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Coinc. 60

    …compared with FibroTest (FT) and liver stiffness measurement (LSM) by transient elastography…

    FibroTest Alcohol HBV HCV +3

  166. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.

    Naveau S et al. · Eur J Gastroenterol Hepatol · 2014 Coinc. 60

    …one of the first composite liver fibrosis markers. This study aims, prospectively…

    FibroTest Alcohol

  167. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Coinc. 60

    …elastography (TE) and biomarkers for liver fibrosis assessment and follow-up of…

    FibroTest HBV

  168. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Coinc. 60

    …AshTest is an appropriate non-invasive alternative to transjugular liver biopsy.

    AshTest Alcohol

  169. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Coinc. 60

    …Evaluation of liver fat was performed using four noninvasive methods: the SteatoTest…

    SteatoTest Metabolic

  170. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.

    Dezanet LNC et al. · Liver Int · 2021 Coinc. 59

    ### Background & Aims Data on liver fibrosis evolution and its involvement in liver

    FibroTest HBV HIV

  171. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Coinc. 59

    …All patients had a liver biopsy. The Hepascore and FibroTest were calculated…

    FibroTest Other

  172. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.

    Sturm N et al. · Liver Int · 2013 Coinc. 59

    ### Background Liver fibrosis, now assessed by liver biopsy or using non-invasive…

    FibroTest HBV HCV

  173. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013 Coinc. 59

    ### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…

    FibroTest HCV

  174. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Coinc. 58

    …is the prediction of metabolic liver disease (MLD) by noninvasive tests (NITs…

    FibroTest NashTest SteatoTest Metabolic

  175. Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Review

    Wong GL et al. · Clin Mol Hepatol · 2015 Coinc. 58

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  176. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. Key publication

    Thabut D et al. · J Hepatol · 2006 Coinc. 58

    …The use of AshTest may reduce the need for liver biopsy, and…

    AshTest Alcohol

  177. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.

    Zarski JP et al. · Liver Int · 2010 Coinc. 58

    …Blood tests could be useful to assess liver fibrosis changes in clinical…

    ActiTest FibroTest HCV

  178. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Coinc. 57

    ActiTest FibroTest HBV

  179. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

    Poynard T et al. · J Hepatol · 2013 Coinc. 57

    …Blinded liver biopsies obtained before retreatment and after maintenance therapy were evaluated…

    ActiTest FibroTest HBV

  180. [Prognosis assessment of alcoholic liver disease: how and why?]. Review

    Trabut JB et al. · Presse Med · 2014 Coinc. 57

    Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…

    FibroTest Alcohol

  181. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Coinc. 57

    …competitor as a biomarker of liver fibrosis in comparison with the standard…

    ActiTest FibroTest SteatoTest Alcohol +3

  182. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Coinc. 56

    ActiTest FibroTest HBV

  183. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Coinc. 56

    …infection or non-HCV-related liver diseases. ### Methods And Results The optimal…

    FibroTest Alcohol HBV HCV +2

  184. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Coinc. 56

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…

    NashTest-2 SteatoTest-2 Metabolic

  185. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Coinc. 56

    ### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  186. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication

    Poynard T et al. · JHEP Rep · 2021 Coinc. 55

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  187. Noninvasive Assessment of Liver Fibrosis. Key publication Review

    Castera L et al. · N Engl J Med · 2025 Coinc. 55

    FibroTest Metabolic

  188. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. Key publication

    Poynard T et al. · Gastro Hep Adv · 2022 Coinc. 55

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 HBV

  189. An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

    Poynard T et al. · Biomedicines · 2025 Coinc. 55

    **Background:** The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  190. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review

    Vilar-Gomez E et al. · J Hepatol · 2018 Coinc. 54

    …Since liver biopsy is invasive, expensive and prone to sampling error, several…

    FibroTest Metabolic

  191. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis

    Houot M et al. · Aliment Pharmacol Ther · 2016 Coinc. 54

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  192. Noninvasive diagnosis in alcohol-related liver disease.

    Hadefi A et al. · Health Sci Rep · 2020 Coinc. 54

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  193. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Coinc. 54

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  194. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Coinc. 53

    …and metabolic-dysfunction-associated steatotic liver disease (MASLD); however, the underlying mechanisms…

    FibroTest Metabolic

  195. [Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Review

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Coinc. 53

    Liver cirrhosis in Mexico is one of the most important causes of…

    FibroTest HCV

  196. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Coinc. 53

    …the prediction of non-alcoholic liver disease by non-invasive blood tests…

    FibroTest NashTest-2 SteatoTest Metabolic

  197. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Coinc. 53

    FibroTest Alcohol HBV HCV +3

  198. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis

    Salkic NN et al. · Am J Gastroenterol · 2014 Coinc. 52

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  199. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Coinc. 52

    Liver biopsy samples, NIT results, and PROs (Short Form-36, Chronic Liver

    FibroTest Metabolic

  200. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Coinc. 52

    FibroTest Other

  201. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Coinc. 52

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  202. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Coinc. 51

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  203. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Coinc. 51

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  204. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication

    · 2014 Coinc. 51

    These are the first guidelines dealing with hepatitis C treatment produced by…

    FibroTest HCV

  205. Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication

    Coinc. 51

    FibroTest HBV HCV

Mostrando la lista completa de resultados. La página se renderiza en el servidor y no está paginada.